PriceTargets.com logo

NASDAQ:STIM - Neuronetics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.00
  • Forecasted Upside: 191.83 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$5.14 As of 10/27/2021 01:00 AM ET
▲ +0.01 (0.19%)

This chart shows the closing price for STIM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Neuronetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STIM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STIM

Analyst Price Target is $15.00
▲ +191.83% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Neuronetics in the last 3 months. The average price target is $15.00, with a high forecast of $21.00 and a low forecast of $12.00. The average price target represents a 191.83% upside from the last price of $5.14.

This chart shows the closing price for STIM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Neuronetics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/5/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/3/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/14/2021JMP SecuritiesReiterated RatingBuy$18.00 ➝ $12.00High
10/13/2021William BlairDowngradeOutperform ➝ Market PerformHigh
10/13/2021Canaccord GenuityLower Price TargetBuy$21.00 ➝ $15.00High
10/13/2021BTIG ResearchDowngradeBuy ➝ NeutralHigh
8/3/2021Piper SandlerLower Price TargetOverweight$21.00 ➝ $12.00High
5/5/2021Canaccord GenuityReiterated RatingBuy$21.00Low
3/2/2021Piper SandlerLower Price TargetOverweight$27.00 ➝ $25.00High
1/27/2021JMP SecuritiesBoost Price TargetOutperform$15.00 ➝ $23.00High
1/22/2021William BlairUpgradeMarket Perform ➝ OutperformHigh
1/21/2021BTIG ResearchBoost Price TargetBuy$14.00 ➝ $21.00High
1/21/2021Piper SandlerBoost Price TargetOverweight$20.00 ➝ $27.00High
1/12/2021Piper SandlerBoost Price TargetOverweight$9.00 ➝ $20.00High
1/8/2021JMP SecuritiesBoost Price Target$10.00 ➝ $15.00High
12/7/2020BTIG ResearchBoost Price TargetBuy$10.00 ➝ $14.00High
11/23/2020Piper SandlerBoost Price TargetOverweight$7.00 ➝ $9.00Medium
11/3/2020Canaccord GenuityReiterated RatingBuy$8.00High
10/26/2020Canaccord GenuityBoost Price TargetBuy$4.00 ➝ $8.00Low
10/6/2020BTIG ResearchBoost Price TargetBuy$6.00 ➝ $10.00High
8/4/2020BTIG ResearchReiterated RatingBuy$6.00High
5/6/2020Canaccord GenuityReiterated RatingBuy$4.00Low
5/5/2020William BlairDowngradeOutperform ➝ Market PerformMedium
5/5/2020BTIG ResearchReiterated RatingBuy$6.00High
4/9/2020BTIG ResearchLower Price Target$11.00 ➝ $6.00Medium
4/9/2020Canaccord GenuityLower Price TargetBuy$7.00 ➝ $4.00High
3/4/2020Piper SandlerLower Price Target$14.00 ➝ $6.00Medium
3/4/2020Canaccord GenuityReiterated RatingBuyHigh
2/6/2020BTIG ResearchInitiated CoverageBuy$11.00High
12/6/2019Piper Jaffray CompaniesReiterated RatingBuyLow
11/6/2019BTIG ResearchLower Price TargetBuy ➝ Average$11.00High
3/6/2019BTIG ResearchReiterated RatingBuy$25.00Low
3/5/2019Piper Jaffray CompaniesLower Price TargetOverweight$35.00 ➝ $28.00High
11/7/2018BTIG ResearchReiterated RatingBuy$33.00High
8/16/2018BTIG ResearchReiterated RatingBuy$33.00Low
8/15/2018JMP SecuritiesBoost Price TargetMarket Outperform ➝ Outperform$36.00 ➝ $40.00Low
8/15/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$33.00 ➝ $36.00Low
7/24/2018Canaccord GenuityInitiated CoverageBuy$33.00Low
7/23/2018JMP SecuritiesInitiated Coverage$26.02$36.00Low
7/23/2018BTIG ResearchInitiated CoverageBuy$33.00Low
7/23/2018William BlairInitiated CoverageOutperformLow
7/23/2018Piper Jaffray CompaniesInitiated CoverageOverweightLow
(Data available from 10/27/2016 forward)

News Sentiment Rating

0.43 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/31/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/30/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2021
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2021
  • 3 very positive mentions
  • 9 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
8/28/2021
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2021
  • 9 very positive mentions
  • 17 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
Mentions as of
10/27/2021

Current Sentiment

  • 9 very positive mentions
  • 17 positive mentions
  • 5 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Neuronetics logo
Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. It operates through United States and International geographical segments. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.
Read More

Today's Range

Now: $5.14
Low: $4.97
High: $5.30

50 Day Range

MA: $6.90
Low: $4.83
High: $8.88

52 Week Range

Now: $5.14
Low: $4.62
High: $22.43

Volume

137,572 shs

Average Volume

493,327 shs

Market Capitalization

$135.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.56

Frequently Asked Questions

What sell-side analysts currently cover shares of Neuronetics?

The following equities research analysts have issued research reports on Neuronetics in the last year: BTIG Research, Canaccord Genuity, JMP Securities, Piper Sandler, William Blair, and Zacks Investment Research.
View the latest analyst ratings for STIM.

What is the current price target for Neuronetics?

4 Wall Street analysts have set twelve-month price targets for Neuronetics in the last year. Their average twelve-month price target is $15.00, suggesting a possible upside of 192.4%. BTIG Research has the highest price target set, predicting STIM will reach $21.00 in the next twelve months. JMP Securities has the lowest price target set, forecasting a price of $12.00 for Neuronetics in the next year.
View the latest price targets for STIM.

What is the current consensus analyst rating for Neuronetics?

Neuronetics currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe STIM will outperform the market and that investors should add to their positions of Neuronetics.
View the latest ratings for STIM.

What other companies compete with Neuronetics?

Other companies that are similar to Neuronetics include SeaSpine, PAVmed, Apyx Medical, UFP Technologies, Soliton, IRadimed, AVITA Medical, Asensus Surgical, Accuray, NeuroPace, ClearPoint Neuro, Utah Medical Products, Assure, CVRx and Retractable Technologies.

How do I contact Neuronetics' investor relations team?

Neuronetics' physical mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company's listed phone number is (610) 640-4202 and its investor relations email address is [email protected] The official website for Neuronetics is www.neurostar.com.